Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Yasuo TOYOZUMI"'
Autor:
Rumiko Tashima, Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama, Yasuhiro Okumura, Masahiro Nakano, Mamiko Fujisue, Yasuo Toyozumi, Nobuyuki Arima
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0119565 (2015)
The Ki-67 index is an important biomarker for indicating the proliferation of cancer cells and is considered to be an effective prognostic factor for breast cancer. However, a standard cut-off point for the Ki-67 index has not yet been established. T
Externí odkaz:
https://doaj.org/article/8e79225136314f1ca8568965674e76a5
Autor:
Miwa, Nagano, Ikuo, Misumi, Koji, Sato, Koichi, Haba, Hiroshi, Yamasaki, Yasuo, Toyozumi, Hiroki, Usuku, Kenichi, Tsujita
Publikováno v:
International Heart Journal. 63:647-650
An 83-year-old man suddenly lost consciousness, and his blood pressure dropped. Results of blood analysis were within normal range. A chest radiograph showed enlargement of the left mediastinum. Computed tomographic scan of the chest showed a large m
Autor:
Yasuo Toyozumi, Kayo Kuyama, Takakazu Sasaguri, Hiroshi Harada, Akira Kurose, Shin-ichi Nakatsuka
Publikováno v:
Medical molecular morphology. 54(3)
Sclerosing mucoepidermoid carcinoma (SMC) is described as a "sclerosing variant" of mucoepidermoid carcinoma, and it is characterized by dense fibrosis and sclerosis of the stroma. SMC with eosinophilia (SMCE) is another and more rare subtype charact
Autor:
Nobuyuki Arima, Yasuo Toyozumi, Tomofumi Osako, Mamiko Fujisue, Yasuhiro Okumura, Yasuyuki Nishiyama, Reiki Nishimura
Publikováno v:
Cancer Research. 78:P2-09
Background: Breast cancer is no longer a single disease with high molecular heterogeneity. Gene profiling has identified at least 4 subtypes: Luminal A, Luminal B, HER2-enriched and basal-like breast cancer. Moreover, immunohistochemistry (IHC) class
Autor:
K Murakami, Mamiko Fujisue, Tomofumi Osako, Yasuo Toyozumi, Yasuhiro Okumura, Nobuyuki Arima, Reiki Nishimura, Yasuyuki Nishiyama
Publikováno v:
Cancer Research. 76:P4-09
Introduction The recent diagnostic modality such as MRI can diagnose a tiny breast lesion even in healthy contralateral breasts. Recently, the rate of contralateral prophylactic mastectomy (CPM) is on the rise in the United States. In Japan, the CPM
Autor:
Kiminari Kawano, Arisa Shiga, Nobuyuki Arima, Tomoko Yamada, Yasuo Toyozumi, Ritsuo Matsumoto
Publikováno v:
The Journal of the Japanese Society of Clinical Cytology. 55:322-328
Autor:
Tomofumi Osako, Yasuo Toyozumi, Nobuyuki Arima, Mamiko Fujisue, Yasuhiro Okumura, Masahiro Nakano, Yasuyuki Nishiyama, Reiki Nishimura
Publikováno v:
Oncology Letters.
Gene profiling has identified at least 4 breast cancer subtypes, including Luminal A, Luminal B, HER2-enriched and basal-like, and immunohistochemistry is used as a guide to determine these subtypes. In the present study, patients with ER-positive, H
Autor:
Mamiko Fujisue, Yasuo Toyozumi, Tomofumi Osako, Reiki Nishimura, Nobuyuki Arima, Masahiro Nakano, Yasuyuki Nishiyama, Yasuhiro Okumura, Rumiko Tashima
Publikováno v:
Oncology. 90:43-50
Objective: In this case-control study, we investigated the most suitable cell counting area and the optimal cutoff point of the Ki-67 index. Methods: Thirty recurrent cases were selected among hormone receptor (HR)-positive/HER2-negative breast cance
Autor:
Masahiro Nakano, Yasuo Toyozumi, Yasuhiro Okumura, Tomofumi Osako, Yasuyuki Nishiyama, Mamiko Fujisue, Nobuyuki Arima, Reiki Nishimura, Rumiko Tashima
Publikováno v:
International Journal of Clinical Oncology. 20:1093-1101
Intraoperative frozen section analysis of the surgical margins during breast-conserving surgery (BCS) for breast cancer can reliably achieve clear surgical margins and prevent re-operations. The aim of this study was to assess intraoperative entire-c
Autor:
Reiki Nishimura, Yasuo Toyozumi, Mamiko Fujisue, Rumiko Tashima, Yasuyuki Nishiyama, Tomofumi Osako, Masahiro Nakano, Nobuyuki Arima
Publikováno v:
Molecular and Clinical Oncology. 2:1062-1068
The Ki-67 index value is a prognostic factor in primary breast cancer and is a proliferation marker that also distinguishes between luminal type A and type B breast cancer. Moreover, a change in Ki-67 index values due to treatment and recurrence is c